Innovative Medicine
-
Janssen Connected Health Challenge Europe 2012 Launching To Spur Healthcare Innovation
Janssen Connected Health Challenge seeks transformational care ideas and offers awards totalling €30,000 to develop winning solutions -
Subcutaneous VELCADE® Approved In the EU for the Treatment of Multiple Myeloma
Simpler, easier route of administration offers improved safety and convenience, with maintained efficacy -
FDA Approves Expansion of Dosing Window to Help Avoid Missed Doses in INVEGA® SUSTENNA® Updated Product Label
Additional Prescribing Information Revisions Also Reflected in Updated Product Label -
-
Johnson & Johnson Symposium Honors 2012 Recipients of the Dr. Paul Janssen Award for Biomedical Research
Dr. Victor Ambros and Dr. Gary Ruvkun Honored for Discovery of microRNAs;Symposium Celebrates the Power of Science to Change the World -
Janssen Research & Development Submits Complete Response to the U.S. FDA on XARELTO® (rivaroxaban) for the Reduction of Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome
Supplemental New Drug Application for XARELTO® to reduce the risk of stent thrombosis in patients with acute coronary syndrome also resubmitted -
-
Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
Compound in Development for Multiple Myeloma -